المؤلفون: Alvarez-Frutos, Lucia, Barriuso, Daniel, Duran, Mercedes, Infante, Mar, Kroemer, Guido, Palacios-Ramirez, Roberto, Senovilla, Laura

المساهمون: Universidad de Valladolid Valladolid (UVa), Métabolisme, Cancer et Immunité (CRC - UMR_S 1138), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École Pratique des Hautes Études (EPHE), Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut Gustave Roussy (IGR), Institut universitaire de France (IUF), Ministère de l'Education nationale, de l’Enseignement supérieur et de la Recherche (M.E.N.E.S.R.), Cancer Research and Personalized Medicine - CARPEM Paris (SIRIC CARPEM), Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpital Cochin AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Necker - Enfants Malades AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut national du cancer (INCa), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), ANR-18-IDEX-0001,Université de Paris,Université de Paris(2018), ANR-21-ESRE-0028,ONCO-PHENO-SCREEN,Next-generation phenotypic screening for oncological applications(2021)

المصدر: ISSN: 2234-943X ; Frontiers in Oncology ; https://hal.science/hal-04596709Test ; Frontiers in Oncology, 2023, 13, pp.1292046. ⟨10.3389/fonc.2023.1292046⟩.

مصطلحات موضوعية: breast cancer, early-stage, cancer progression, metastasis, omics, biomarkers Frontiers in Oncology frontiersin.org 01, [SDV]Life Sciences [q-bio]

الوصف: International audience ; Breast cancer is the most common malignant neoplasm in women. Despite progress to date, 700,000 women worldwide died of this disease in 2020. Apparently, the prognostic markers currently used in the clinic are not sufficient to determine the most appropriate treatment. For this reason, great efforts have been made in recent years to identify new molecular biomarkers that will allow more precise and personalized therapeutic decisions in both primary and recurrent breast cancers. These molecular biomarkers include genetic and post-transcriptional alterations, changes in protein expression, as well as metabolic, immunological or microbial changes identified by multiple omics technologies (e.g., genomics, epigenomics, transcriptomics, proteomics, glycomics, metabolomics, lipidomics, immunomics and microbiomics). This review summarizes studies based on omics analysis that have identified new biomarkers for diagnosis, patient stratification, differentiation between stages of tumor development (initiation, progression, and metastasis/recurrence), and their relevance for treatment selection. Furthermore, this review highlights the importance of clinical trials based on multiomics studies and the need to advance in this direction in order to establish personalized therapies and prolong disease-free survival of these patients in the future.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38169859; hal-04596709; https://hal.science/hal-04596709Test; https://hal.science/hal-04596709/documentTest; https://hal.science/hal-04596709/file/10758476.pdfTest; PUBMED: 38169859; PUBMEDCENTRAL: PMC10758476

الإتاحة: https://doi.org/10.3389/fonc.2023.1292046Test
https://hal.science/hal-04596709Test
https://hal.science/hal-04596709/documentTest
https://hal.science/hal-04596709/file/10758476.pdfTest

المؤلفون: Alvarez-Frutos, Lucia, Barriuso, Daniel, Duran, Mercedes, Infante, Mar, Kroemer, Guido, Palacios-Ramirez, Roberto, Senovilla, Laura

المصدر: Frontiers in Oncology; 2024, p01-19, 19p

مصطلحات موضوعية: MULTIOMICS, PROGNOSIS, PROGRESSION-free survival, PROTEIN expression, LIPIDOMICS

مستخلص: Breast cancer is the most common malignant neoplasm in women. Despite progress to date, 700,000 women worldwide died of this disease in 2020. Apparently, the prognostic markers currently used in the clinic are not sufficient to determine the most appropriate treatment. For this reason, great efforts have been made in recent years to identify new molecular biomarkers that will allow more precise and personalized therapeutic decisions in both primary and recurrent breast cancers. These molecular biomarkers include genetic and post-transcriptional alterations, changes in protein expression, as well as metabolic, immunological or microbial changes identified by multiple omics technologies (e.g., genomics, epigenomics, transcriptomics, proteomics, glycomics, metabolomics, lipidomics, immunomics and microbiomics). This review summarizes studies based on omics analysis that have identified new biomarkers for diagnosis, patient stratification, differentiation between stages of tumor development (initiation, progression, and metastasis/recurrence), and their relevance for treatment selection. Furthermore, this review highlights the importance of clinical trials based on multiomics studies and the need to advance in this direction in order to establish personalized therapies and prolong disease-free survival of these patients in the future. [ABSTRACT FROM AUTHOR]

: Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)